<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id><journal-id journal-id-type="publisher-id">diacare</journal-id><journal-title>Diabetes Care</journal-title><issn pub-type="ppub">0149-5992</issn><issn pub-type="epub">1935-5548</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">3191847</article-id><article-id pub-id-type="doi">10.2337/dc07-2079</article-id><article-id pub-id-type="pmid">18523145</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pathophysiology/Complications</subject></subj-group></article-categories><title-group><article-title>Prognostic Value of the Insertion/Deletion Polymorphism of the <italic>ACE</italic> Gene in Type 2 Diabetic Subjects</article-title><subtitle>Results from the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique (SURDIAGENE) studies </subtitle></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hadjadj</surname><given-names>Samy</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Fumeron</surname><given-names>Fr&#x000e9;d&#x000e9;ric</given-names></name><degrees>PHD</degrees><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Roussel</surname><given-names>Ronan</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Saulnier</surname><given-names>Pierre-Jean</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Gallois</surname><given-names>Yves</given-names></name><degrees>PHARMD, PHD</degrees><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Ankotche</surname><given-names>Amos</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Travert</surname><given-names>Florence</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Khalil</surname><given-names>Charbel Abi</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Miot</surname><given-names>Aur&#x000e9;lie</given-names></name><degrees>MSC</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Alhenc-Gelas</surname><given-names>Fran&#x000e7;ois</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Lievre</surname><given-names>Michel</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Marre</surname><given-names>Michel</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><collab>on behalf of the DIABHYCAR, DIAB2NEPHROGENE, and SURDIAGENE study groups</collab></contrib></contrib-group><aff id="aff1"><label>1</label>Centre Hospitalier Universitaire Poitiers, Endocrinology, Diabetology, Poitiers, France</aff><aff id="aff2"><label>2</label>Institut National de la Sant&#x000e9; et de la Recherche M&#x000e9;dicale, U927, Poitiers, France</aff><aff id="aff3"><label>3</label>Institut National de la Sant&#x000e9; et de la Recherche M&#x000e9;dicale, U695, Paris, France</aff><aff id="aff4"><label>4</label>Unit&#x000e9; de Formation et de Recherche M&#x000e9;decine Xavier Bichat, Universit&#x000e9; Paris 7 Diderot, Paris, France</aff><aff id="aff5"><label>5</label>Endocrinologie-Diabetologie-Nutrition, H&#x000f4;pital Bichat, Assistance Publique-H&#x000f4;pitaux de Paris, Paris, France</aff><aff id="aff6"><label>6</label>Centre Hospitalier Universitaire Poitiers, France and Institut National de la Sant&#x000e9; et de la Recherche M&#x000e9;dicale, CIC 0802, Poitiers, France</aff><aff id="aff7"><label>7</label>Biochemistry, Centre Hospitalier Universitaire, Angers, France</aff><aff id="aff8"><label>8</label>CIC Bichat, Assistance Publique-H&#x000f4;pitaux de Paris, Paris, France</aff><aff id="aff9"><label>9</label>Institut National de la Sant&#x000e9; et de la Recherche M&#x000e9;dicale, U652, Paris, France</aff><aff id="aff10"><label>10</label>Facult&#x000e9; de M&#x000e9;decine La&#x000eb;nnec, Universit&#x000e9; Claude Bernard Lyon 1, Lyon, France</aff><author-notes><fn><p>Corresponding author: Samy Hadjadj, <email>s.hadjadj&#x00040;chu-poitiers.fr</email></p></fn></author-notes><pub-date pub-type="ppub"><month>9</month><year>2008</year></pub-date><volume>31</volume><issue>9</issue><fpage>1847</fpage><lpage>1852</lpage><history><date date-type="received"><day>30</day><month>10</month><year>2007</year></date><date date-type="accepted"><day>21</day><month>5</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008, DIABETES CARE</copyright-statement><license license-type="open-access"><p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link> for details.</p></license></permissions><self-uri xlink:title="pdf" xlink:href="zdc00908001847.pdf"/><abstract><p><bold>OBJECTIVE</bold>&#x02014;We tested whether determination of the <italic>ACE</italic> insertion/deletion polymorphism is useful for renal and cardiovascular prognoses of type 2 diabetic subjects.</p><p><bold>RESEARCH DESIGN AND METHODS</bold>&#x02014;The French participants (3,126 of 4,912) in the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) trial were studied for their prognosis over 4 years according to their <italic>ACE</italic> insertion/deletion polymorphism. We used two cohorts of French type 2 diabetic patients for replication: a 3-year follow-up study (<italic>n</italic> &#x0003d; 917; Survie, Diabete de type 2 et Genetique &#x0005b;SURDIAGENE&#x0005d; study) and a case-control study on diabetic nephropathy (<italic>n</italic> &#x0003d; 1,277; Diabete de type 2, Nephropathie et Genetique &#x0005b;DIAB2NEPHROGENE&#x0005d; study). We investigated the effect of the insertion/deletion polymorphism on the primary outcome in the DIABHYCAR trial (defined as the first of the following events to occur: cardiovascular death, nonfatal myocardial infarction, stroke, heart failure leading to hospital admission, or end-stage renal failure) and its components.</p><p><bold>RESULTS</bold>&#x02014;In DIABHYCAR, the primary outcome and most of its components were not affected by the <italic>ACE</italic> insertion/deletion genotype. Only renal outcome was favored by the I allele (<italic>P</italic> &#x0003d; 0.03). The risk of myocardial infarction was not affected by <italic>ACE</italic> genotype, but the probability of fatal outcome increased with the number of D alleles (<italic>P</italic> &#x0003c; 0.03). In SURDIAGENE, the association between the <italic>ACE</italic> I allele and renal outcome was not replicated. In DIAB2NEPHROGENE, no association was found with nephropathy.</p><p><bold>CONCLUSIONS</bold>&#x02014;We were not able to demonstrate the manifest usefulness of the <italic>ACE</italic> insertion/deletion polymorphism for the prognosis of type 2 diabetic subjects.</p></abstract></article-meta><notes><fn-group><fn><p>Published ahead of print at <ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org">http://care.diabetesjournals.org</ext-link> on 3 June 2008.</p><p>M.M. and M.L. received funds from sanofi aventis for urinary albumin assays and data management for the DIABHYCAR study.</p><p>Details on the DIABHYCAR trial committees are available from previous publications (refs. <xref ref-type="bibr" rid="r9">9</xref> and <xref ref-type="bibr" rid="r18">18</xref>).</p><p>The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked &#x0201c;advertisement&#x0201d; in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.</p></fn></fn-group></notes></front><body><p>The reduced life expectancy of diabetic subjects is due mostly to renal and cardiovascular outcomes (<xref ref-type="bibr" rid="r1">1</xref>). Renal risk threatens type 1 diabetic subjects, whereas cardiovascular risk is typical of type 2 diabetes. However, these two risks are intimately linked, as microalbuminuria is predictive of diabetic nephropathy in type 1 diabetes (<xref ref-type="bibr" rid="r2">2</xref>) and of cardiovascular death principally in type 2 diabetes (<xref ref-type="bibr" rid="r3">3</xref>). Microalbuminuria, a marker of early renal involvement, indicates generalized vascular leakage and endothelial dysfunction (<xref ref-type="bibr" rid="r4">4</xref>), likely to promote cardiovascular events.</p><p>ACE regulates microcirculation within the kidney and myocardium by generating angiotensin 2, a vasoconstrictor peptide with profibrotic and procoagulant properties, and by breaking down kinins, which have the opposite properties (<xref ref-type="bibr" rid="r5">5</xref>). Pharmacological inhibition of ACE protects against renal and cardiovascular risks in diabetes: it protects against nephropathy (<xref ref-type="bibr" rid="r6">6</xref>) and limits progression to end-stage renal failure (ESRF) (<xref ref-type="bibr" rid="r7">7</xref>) mostly in type 1 diabetes, whereas it reduces cardiovascular risk (mainly by protecting against coronary heart disease) in type 2 diabetes (<xref ref-type="bibr" rid="r8">8</xref>). Interestingly, the doses of ACE inhibitors required to reduce cardiovascular risk are higher than those required to decrease microalbuminuria (<xref ref-type="bibr" rid="r9">9</xref>) and renal risk (<xref ref-type="bibr" rid="r10">10</xref>).</p><p>The <italic>ACE</italic> gene is an excellent candidate for determining prognosis for cardiovascular and renal risks: a single insertion/deletion polymorphism in intron 16 (rs1799752) of a 287-bp Alu sequence accounts for half of the interindividual variance of the circulating and cellular activities of this enzyme. ACE activity is highest in subjects homozygous for the D allele (DD genotype), lowest in those homozygous for the I allele (II genotype), and intermediate in heterozygotes (ID genotype). Although its prognostic value for myocardial infarction is controversial in the general population (<xref ref-type="bibr" rid="r11">11</xref>,<xref ref-type="bibr" rid="r12">12</xref>), its impact for renal prognosis is well established in type 1 diabetes (<xref ref-type="bibr" rid="r13">13</xref>&#x02013;<xref ref-type="bibr" rid="r16">16</xref>). Clinical trials in type 1 diabetes have suggested that patients with the II genotype display a better renal response to ACE inhibition than other patients (<xref ref-type="bibr" rid="r17">17</xref>).</p><p>We therefore wondered whether genotyping <italic>ACE</italic> for its insertion/deletion polymorphism would markedly contribute to individualization of renal and cardiovascular prognoses of type 2 diabetic subjects with raised urinary albumin concentrations in a substudy of the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) trial (<xref ref-type="bibr" rid="r9">9</xref>), a clinical trial comparing a low dose of ramipril with placebo. We assessed the impact of the <italic>ACE</italic> insertion/deletion genotype on the principal outcome, a composite of cardiovascular death, nonfatal myocardial infarction, stroke, heart failure leading to hospitalization, and ESRF, and on each of its components. To replicate our initial findings, we tested the same hypothesis on two independent cohorts of French type 2 diabetic patients: a single-center follow-up study on cardiovascular and renal outcomes (the Survie, Diabete de type 2 et Genetique &#x0005b;SURDIAGENE&#x0005d; study), and a multicenter case-control study on diabetic nephropathy (the Diabete de type 2, Nephropathie et Genetique &#x0005b;DIAB2NEPHROGENE&#x0005d; study).</p><sec><title>RESEARCH DESIGN AND METHODS</title><sec><title>Primary cohort</title><p>The DIABHYCAR study design and results have been reported elsewhere (<xref ref-type="bibr" rid="r9">9</xref>,<xref ref-type="bibr" rid="r18">18</xref>). Participants were selected on the basis of type 2 diabetes, treatment with oral antidiabetic agents on enrollment, high urinary albumin concentration (76&#x00025; microalbuminuric and 24&#x00025; macroalbuminuric patients), age &#x02265;50 years, and serum creatinine concentration &#x02264;150 &#x003bc;mol/l. French patients were selected by their general practitioners, and &#x02265;98&#x00025; were Caucasians. The tested drug was low-dose ramipril (1.25 mg/day). The primary end point was the combined incidence of cardiovascular death, nonfatal acute myocardial infarction, stroke, heart failure leading to hospitalization, and ESRF (defined as a requirement for dialysis or kidney transplant). These outcomes were also analyzed separately. All events were adjudicated by an independent clinical event committee (<xref ref-type="bibr" rid="r18">18</xref>). Ramipril proved to be ineffective (<xref ref-type="bibr" rid="r9">9</xref>).</p><p>The genetic substudy of DIABHYCAR was conducted in the French participants only for logistic reasons. All gave written consent on a form separate from the trial consent form. As preliminary data had suggested that an <italic>ACE</italic> insertion/deletion polymorphism might be associated with the risk of myocardial infarction (<xref ref-type="bibr" rid="r11">11</xref>) and diabetic nephropathy (<xref ref-type="bibr" rid="r19">19</xref>), this analysis was planned prospectively (<xref ref-type="bibr" rid="r20">20</xref>). By assuming a D allele frequency of 60&#x00025; and a composite event rate of 20&#x00025; over the study period (<xref ref-type="bibr" rid="r20">20</xref>), the sample size of the French subgroup (<xref ref-type="bibr" rid="r18">18</xref>) gave an a priori power of 94&#x00025; for detecting a 25&#x00025; difference in the risk of morbid events among patients with the DD genotype and those with the ID or II genotype. The study design was approved by the Angers University Ethics Committee.</p></sec><sec><title>Replication cohorts</title><p>SURDIAGENE was a prospective single-center follow-up study of type 2 diabetic patients regularly being seen at the Diabetes Department at Poitiers University Hospital, in 2001&#x02013;2007, designed to identify the genetic determinants of microvascular and macrovascular diabetic complications in type 2 diabetes. The main exclusion criteria were residence outside the Poitiers area and/or evidence of nondiabetic kidney disease. Clinical events corresponding to the primary end point of the DIABHYCAR study were recorded prospectively from patients&#x02019; hospital records and interviews with general practitioners.</p><p>DIAB2NEPHROGENE was a multicenter case-control study (15 diabetes and 5 nephrology centers in France between 2001 and 2004 &#x0005b;additional information can be found in an online appendix at <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2337/dc07-2079">http://dx.doi.org/10.2337/dc07-2079</ext-link>&#x0005d;) designed to assess the genetic determinants of diabetic nephropathy in type 2 diabetes. Case patients were type 2 diabetic patients with high urinary albumin concentrations (&#x02265;20 mg/l or 30 mg/24 h on two of three sterile urine collections) and retinopathy. Control subjects were type 2 diabetic patients of the same geographic origin with urinary albumin concentrations &#x0003c;20 mg/l or 30 mg/24 h on two of three sterile urine collections who were not receiving ACE inhibitors and/or angiotensin receptor blockers and who had retinopathy and/or known diabetes duration &#x02265;20 years.</p><p>The DIAB2NEPHROGENE and SURDIAGENE studies were approved by the Poitiers University Ethics Committee. All participants gave written informed consent.</p></sec><sec><title>Biological determinations</title><p>DNA extraction and genotyping methods have been described elsewhere (<xref ref-type="bibr" rid="r13">13</xref>). A1C was determined centrally using a high-performance liquid chromatography method: a DIAMAT analyzer (normal values 4.0&#x02013;5.6&#x00025;; Bio-Rad, Richmond, CA) in the DIABHYCAR study and ADAMS A1C HA-8160 analyzer (normal values 4.0&#x02013;6.0&#x00025;; Menarini, Florence, Italy), in the DIAB2NEPHROGENE and SURDIAGENE studies. Urinary albumin was measured by nephelometry. Serum creatinine, lipid (total and HDL cholesterol, triglycerides, and calculated LDL cholesterol), and highly sensitive C-reactive protein concentrations were determined centrally in the fasting state using a colorimetric method, running on an automated analyzer (Kone Optima; Thermo Clinical Labsystems, Vantaa, Finland), and a nephelometric method (N High Sensitivity CRP; Dade Behring, Marburg, Germany), respectively.</p></sec><sec><title>Statistical analysis</title><p>In the DIABHYCAR and SURDIAGENE studies, we considered the time to occurrence of a predefined combined primary end point and of each of its components during the study. For the combined end point, we considered only the event that occurred first. A Kaplan-Meier survival curve was constructed to assess the effect of <italic>ACE</italic> genotype on the occurrence of end points with time to the event as the outcome variable and censoring at the end of the study. A multivariate Cox proportional hazards model was used to analyze the effect of <italic>ACE</italic> genotype and other covariates on study outcomes. We also used &#x003c7;<sup>2</sup> and &#x003c7;<sup>2</sup> for trend tests, ANOVA after log-transformation if required, and multivariate regression analysis. All statistical analyses were performed with Statview 5 (SAS Institute, Cary, NC).</p></sec></sec><sec><title>RESULTS</title><sec><title>DIABHYCAR trial</title><p>Baseline characteristics are presented according to the <italic>ACE</italic> insertion/deletion polymorphism in <xref ref-type="table" rid="t1">Table 1</xref>. The <italic>ACE</italic> insertion/deletion polymorphism was associated with a personal history of myocardial infarction (&#x003c7;<sup>2</sup> 6.53; <italic>P</italic> &#x0003d; 0.038), with the I allele being more frequent among participants with previous myocardial infarction than among others (49.4 vs. 40.6&#x00025;, <italic>P</italic> &#x0003d; 0.01). This association persisted (<italic>P</italic> &#x0003d; 0.0076) in multiple logistic regression analysis after sex, systolic blood pressure, serum creatinine concentration, urinary albumin concentration, and HDL cholesterol concentration were considered and also after forcing age, A1C, and smoking into the model.</p><p>During follow-up (median 4 years; range 0&#x02013;6 years), a primary outcome occurred in 495 participants (<xref ref-type="table" rid="t2">Table 2</xref>). The occurrence of the primary combined outcome did not differ among <italic>ACE</italic> genotypes (supplemental Fig. 1<italic>A</italic>, available in an online appendix), with no interaction with treatment group (ramipril or placebo). No association was found regarding the incidence of cardiovascular death, myocardial infarction, stroke, and heart failure leading to hospitalization (supplemental Fig. 1<italic>B&#x02013;E</italic>). However, the <italic>ACE</italic> genotype affected the risk of ESRF (supplemental Fig. 1<italic>F</italic>) with fewer occurrences of ESRF among patients with the ID or the DD than the II genotype (<italic>P</italic> &#x0003d; 0.034). Results were not affected by multivariate adjustment (supplemental Table 1, available in the online appendix); a higher risk for ESRF persisted for the II genotype (<italic>P</italic> &#x0003d; 0.018).</p><p>Eleven of the 95 myocardial infarctions occurring during the trial were fatal: 1 of the 18 patients with the II genotype, 3 of the 49 patients with the ID genotype, and 7 of the 28 patients with the DD genotype (&#x003c7;<sup>2</sup> for trend <italic>P</italic> &#x0003d; 0.024). D allele frequency was 0.85 in those with fatal myocardial infarctions and 0.52 in those with nonfatal myocardial infarctions (<italic>P</italic> &#x0003d; 0.005). The deleterious effect of the DD genotype on postmyocardial infarction mortality risk persisted in multivariate regression analysis (adjusted relative risk vs. ID or II genotype 9.62 &#x0005b;95&#x00025; CI 2.11&#x02013;43.9&#x0005d;) (supplemental Table 2, available in the online appendix).</p><sec><title>Updated power calculation.</title><p>Given the observed incidence of the primary outcome of 15.8&#x00025; (495 events in 3,126 subjects), the study had 80&#x00025; power for detecting a 25&#x00025; difference between the event rates in the 1,114 patients with the DD genotype and the 2,012 patients with the II or ID genotype.</p></sec></sec><sec><title>SURDIAGENE cohort</title><p>The baseline characteristics of the 917 participants according to the <italic>ACE</italic> insertion/deletion polymorphism are presented in <xref ref-type="table" rid="t3">Table 3</xref>. No association was found between the <italic>ACE</italic> insertion/deletion polymorphism and diabetic nephropathy or personal history of myocardial infarction.</p><p>Median follow-up was 3 years (range 0&#x02013;6 years). A primary event occurred in 191 participants, and 108 patients died (<xref ref-type="table" rid="t4">Table 4</xref>). The occurrence rate of the primary combined end point did not differ among the <italic>ACE</italic> genotypes. No association was found for the incidence of myocardial infarction, stroke, heart failure leading to hospitalization, and ESRF. However, cardiovascular death occurred more frequently in patients with the II genotype compared with patients with the ID or DD genotypes (<italic>P</italic> &#x0003d; 0.057).</p><p>Eight of the 31 patients having a myocardial infarction during the follow-up period died: none of the 5 patients with the II genotype, 3 of the 14 patients with the ID genotype, and 5 of the 12 patients with the DD genotype (&#x003c7;<sup>2</sup> for trend <italic>P</italic> &#x0003d; 0.0631). D allele frequency was 0.81 in those having fatal myocardial infarctions and 0.54 in those having nonfatal myocardial infarctions (<italic>P</italic> &#x0003d; 0.057). The deleterious effect of the DD genotype on postmyocardial infarction mortality risk was not significant (relative risk vs. ID or II genotype 2.16 &#x0005b;95&#x00025; CI 0.60&#x02013;7.79&#x0005d;).</p></sec><sec><title>DIAB2NEPHROGENE study</title><p>We considered a total of 863 case patients and 414 control subjects. Their baseline characteristics are summarized according to the <italic>ACE</italic> insertion/deletion polymorphisms in supplemental Table 3. No association was found between the <italic>ACE</italic> insertion/deletion polymorphism and diabetic nephropathy or ESRF. The <italic>ACE</italic> insertion/deletion polymorphism was not significantly associated with a personal history of myocardial infarction (data not shown).</p></sec></sec><sec><title>CONCLUSIONS</title><p>The data from our large-scale trial suggest that the <italic>ACE</italic> genotype in type 2 diabetic patients with a high cardiovascular and renal risk is of little value for the determination of prognosis. We found that the <italic>ACE</italic> insertion/deletion genotype had no impact on the occurrence of a composite end point including cardiovascular death, myocardial infarction, stroke, heart failure leading to hospitalization, and ESRF. The lack of impact of the <italic>ACE</italic> insertion/deletion polymorphism on the global cardiorenal prognosis of type 2 diabetic subjects was replicated in two additional cohorts. These are the first prospective follow-up studies on the impact of the <italic>ACE</italic> insertion/deletion polymorphism on cardiovascular and renal outcomes in people with type 2 diabetes.</p><p>French participants in the DIABHYCAR trial were enrolled by their general practitioners. This ensured that the DIABHYCAR cohort was representative, as &#x0003e;90&#x00025; of French individuals with type 2 diabetes are treated by their general practitioners. In contrast, the participants in the other two studies were recruited from hospitals (SURDIAGENE and DIAB2NEPHROGENE) and more frequently had cardiovascular diseases. This difference in the prevalence of complications between hospital-based and population-based studies has been reported before (<xref ref-type="bibr" rid="r21">21</xref>).</p><p>The <italic>ACE</italic> insertion/deletion polymorphism appeared ideal to introduce some genetic components into the calculation of cardiovascular and renal risks, particularly in type 2 diabetes. However, the present results do not support this possibility. Thus, the widespread use of this polymorphism for individualizing cardiovascular and renal prognoses in type 2 diabetes seems ruled out by our findings.</p><p>The association between the <italic>ACE</italic> I allele and previous myocardial infarction in DIABHYCAR participants went against our hypothesis, although it was not replicated in the other two cohorts. For myocardial infarction, conflicting data have been obtained in case-control studies (<xref ref-type="bibr" rid="r11">11</xref>,<xref ref-type="bibr" rid="r12">12</xref>). However, we must consider the possibility that a selection bias might have been operating in DIABHYCAR, in which the I allele was unexpectedly related to a history of myocardial infarction. This finding did not fit with the so-called mendelian randomization principle. In DIABHYCAR and SURDIAGENE, death after myocardial infarction was related to the D allele. Only small numbers of events were recorded, but <italic>ACE</italic> D allele frequency was higher in those dying after myocardial infarction (79 vs. 55&#x00025;); this difference was significant (<italic>P</italic> &#x0003d; 0.005) when the two studies were pooled. This result is consistent with an autopsy study conducted in Belfast: individuals who died of coronary heart disease displayed the DD genotype more frequently than the ID or II genotypes (<xref ref-type="bibr" rid="r22">22</xref>). Thus, we can speculate that type 2 diabetic patients with the highest cardiovascular risk, favored by the DD genotype, were not included in the DIABHYCAR trial because of premature death. This may account for the statistically significant but not clinically valuable association between the <italic>ACE</italic> D allele and myocardial infarction reported in a meta-analysis of several cross-sectional studies (<xref ref-type="bibr" rid="r12">12</xref>). However, these are only secondary end points, and this analysis should be considered as exploratory only.</p><p>We and others have shown through follow-up and experimental studies (<xref ref-type="bibr" rid="r14">14</xref>&#x02013;<xref ref-type="bibr" rid="r16">16</xref>) that the <italic>ACE</italic> II genotype protects against renal failure in type 1 diabetes. The association of the II genotype with ESRF in DIABHYCAR, contradicting this hypothesis, was not replicated in the SURDIAGENE cohort. Thus, the possibility of a chance finding is likely. As previously suggested for Caucasians (<xref ref-type="bibr" rid="r23">23</xref>), our results do not support the theory that renal involvement is related to the <italic>ACE</italic> insertion/deletion polymorphism in type 2 diabetes, contrary to type 1 diabetes.</p><p>In summary, we were not able to identify the <italic>ACE</italic> insertion/deletion polymorphism as a marker for the cardiovascular and renal prognosis of patients with type 2 diabetes, even if an effect of modest amplitude could have been missed owing to insufficient statistical power. Although of great interest for pathophysiological studies, this genetic variant does not seem ready for use in routine clinical practice.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="PMC_1" content-type="local-data"><caption><title>Online-Only Appendix</title></caption><media mimetype="text" mime-subtype="html" xlink:href="dc07-2079_index.html"/><media xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="dc07-2079_diabetescare.doc"/></supplementary-material></sec></body><back><ack><p>The DIABHYCAR trial was supported by grants from sanofi aventis (Paris), Programme Hospitalier de Recherche Clinique (PHRC)-Angers 1996 (French Ministry of Health), and the Association Fran&#x000e7;aise des Diab&#x000e9;tiques (AFD) (Research Grant 2004). The DIAB2NEPHROGENE and SURDIAGENE studies were supported by grants from PHRC-Poitiers 2004, and AFD (Research Grant 2003). The Association Diab&#x000e8;te Risque Vasculaire (Paris, France) and Groupe d'Etude des Maladies M&#x000e9;taboliques et Syst&#x000e9;miques (Poitiers, France) supported the present studies.</p><p>We thank all of the patients and physicians who took part in this study, Vanessa Laneuze, Cecile Demer (Poitiers), and Fran&#x000e7;oise Defrance (Paris) for secretarial help and Julie Sappa of Alex Edelman &#x00026; Associates for checking our English. S. Ragot and J. Guilhot (CIC Poitiers), E. Rogeon, F, Abriat, and the staff of the Diabetes Department at Poitiers are acknowledged for their help with data collection and monitoring and S. Leroux and G. Mauco (Institut National de la Sant&#x000e9; et de la Recherche M&#x000e9;dicale ERM 324 and Biochemistry&#x02013;Poitiers) for biological determinations.</p></ack><ref-list><title>References</title><ref id="r1"><label>1</label><citation citation-type="journal">Booth GL, Kapral MK, Fung K, Tu JV: Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. <source>Lancet</source><volume>368</volume>:<fpage>29</fpage>&#x02013;36, <year>2006</year><pub-id pub-id-type="pmid">16815377</pub-id></citation></ref><ref id="r2"><label>2</label><citation citation-type="journal">Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H: Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. <source>Lancet</source><volume>1</volume>:<fpage>1430</fpage>&#x02013;1432, <year>1982</year><pub-id pub-id-type="pmid">6123720</pub-id></citation></ref><ref id="r3"><label>3</label><citation citation-type="journal">Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. <source>N Engl J Med</source><volume>310</volume>:<fpage>356</fpage>&#x02013;360, <year>1984</year><pub-id pub-id-type="pmid">6690964</pub-id></citation></ref><ref id="r4"><label>4</label><citation citation-type="journal">Stehouwer CD, Smulders YM: Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. <source>J Am Soc Nephrol</source><volume>17</volume>:<fpage>2106</fpage>&#x02013;2111, <year>2006</year><pub-id pub-id-type="pmid">16825333</pub-id></citation></ref><ref id="r5"><label>5</label><citation citation-type="journal">Erdos EG: Angiotensin I converting enzyme and the changes in our concepts through the years: Lewis K. Dahl Memorial Lecture. <source>Hypertension</source><volume>16</volume>:<fpage>363</fpage>&#x02013;370, <year>1990</year><pub-id pub-id-type="pmid">2170273</pub-id></citation></ref><ref id="r6"><label>6</label><citation citation-type="journal">Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. <source>Ann Intern Med</source><volume>134</volume>:<fpage>370</fpage>&#x02013;379, <year>2001</year><pub-id pub-id-type="pmid">11242497</pub-id></citation></ref><ref id="r7"><label>7</label><citation citation-type="journal">Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. <source>N Engl J Med</source><volume>329</volume>:<fpage>1456</fpage>&#x02013;1462, <year>1993</year><pub-id pub-id-type="pmid">8413456</pub-id></citation></ref><ref id="r8"><label>8</label><citation citation-type="journal">Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy: Heart Outcomes Prevention Evaluation Study Investigators. <source>Lancet</source><volume>355</volume>:<fpage>253</fpage>&#x02013;259, <year>2000</year><pub-id pub-id-type="pmid">10675071</pub-id></citation></ref><ref id="r9"><label>9</label><citation citation-type="journal">Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Menard J: Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). <source>BMJ</source><volume>328</volume>: <fpage>495</fpage>, <year>2004</year><pub-id pub-id-type="pmid">14960504</pub-id></citation></ref><ref id="r10"><label>10</label><citation citation-type="journal">Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. <source>Lancet</source><volume>354</volume>:<fpage>359</fpage>&#x02013;364, <year>1999</year><pub-id pub-id-type="pmid">10437863</pub-id></citation></ref><ref id="r11"><label>11</label><citation citation-type="journal">Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F: Deletion Insertion in the gene for angiotensin converting enzyme is a potent risk factor for myocardial infarction. <source>Nature</source><volume>359</volume>:<fpage>641</fpage>&#x02013;644, <year>1992</year><pub-id pub-id-type="pmid">1328889</pub-id></citation></ref><ref id="r12"><label>12</label><citation citation-type="journal">Keavney B, McKenzie C, Parish S, Palmer A, Clark S, Youngman L, Del&#x000e9;pine M, Lathrop M, Peto R, Collins R, International Studies of Infarct Survival (ISIS) Collaborators: Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. <source>Lancet</source><volume>355</volume>:<fpage>434</fpage>&#x02013;442, <year>2000</year><pub-id pub-id-type="pmid">10841123</pub-id></citation></ref><ref id="r13"><label>13</label><citation citation-type="journal">Marre M, Jeunemaitre X, Gallois Y, Rodier M, Chatellier G, Sert C, Dusselier L, Kahal Z, Chaillous L, Halimi S, Muller A, Sackmann H, Bauduceau B, Bled F, Passa P, Alhenc-Gelas F: Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. <source>J Clin Invest</source><volume>99</volume>:<fpage>1585</fpage>&#x02013;1595, <year>1997</year><pub-id pub-id-type="pmid">9120002</pub-id></citation></ref><ref id="r14"><label>14</label><citation citation-type="journal">Boright AP, Paterson AD, Mirea L, Bull SB, Mowjoodi A, Scherer SW, Zinman B: Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study. <source>Diabetes</source><volume>54</volume>:<fpage>1238</fpage>&#x02013;1244, <year>2005</year><pub-id pub-id-type="pmid">15793268</pub-id></citation></ref><ref id="r15"><label>15</label><citation citation-type="journal">Hadjadj S, Belloum R, Bouhanick B, Gallois Y, Guilloteau G, Chatellier G, Alhenc-Gelas F, Marre M: Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: a prospective study. <source>J Am Soc Nephrol</source><volume>12</volume>:<fpage>541</fpage>&#x02013;549, <year>2001</year><pub-id pub-id-type="pmid">11181802</pub-id></citation></ref><ref id="r16"><label>16</label><citation citation-type="journal">Huang W, Gallois Y, Bouby N, Bruneval P, Heudes D, Belair MF, Krege JH, Meneton P, Marre M, Smithies O, Alhenc-Gelas F: Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. <source>Proc Natl Acad Sci USA</source><volume>98</volume>:<fpage>13330</fpage>&#x02013;13334, <year>2001</year><pub-id pub-id-type="pmid">11687636</pub-id></citation></ref><ref id="r17"><label>17</label><citation citation-type="journal">Parving H-H, Jacobsen P, Tarnow L, Rossing P, Lecerf L, Poirier O, Cambien F: Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow-up study. <source>BMJ</source><volume>313</volume>:<fpage>591</fpage>&#x02013;594, <year>1996</year><pub-id pub-id-type="pmid">8806248</pub-id></citation></ref><ref id="r18"><label>18</label><citation citation-type="journal">Li&#x000e8;vre M, Marre M, Chatellier G, Plouin P-F, R&#x000e9;glier J-C, Richardson L, Bugnard F, Vasmant D, DIABHYCAR Study Group: The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. <source>Control Clin Trials</source><volume>21</volume>:<fpage>383</fpage>&#x02013;396, <year>2000</year><pub-id pub-id-type="pmid">10913814</pub-id></citation></ref><ref id="r19"><label>19</label><citation citation-type="journal">Marre M, Bernadet P, Gallois Y, Savagner F, Guyene TT, Hallab M, Cambien F, Passa P, Alhenc-Gelas F: Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. <source>Diabetes</source><volume>43</volume>:<fpage>384</fpage>&#x02013;388, <year>1994</year><pub-id pub-id-type="pmid">8314010</pub-id></citation></ref><ref id="r20"><label>20</label><citation citation-type="journal">Passa P, Chatellier G: The DIAB-HYCAR Study. <source>Diabetologia</source><volume>39</volume>:<fpage>1662</fpage>&#x02013;1667, <year>1996</year><pub-id pub-id-type="pmid">9081852</pub-id></citation></ref><ref id="r21"><label>21</label><citation citation-type="journal">Marre M, Lievre M, Vasmant D, Gallois Y, Hadjadj S, Reglier JC, Chatellier G, Mann J, Viberti GC, Passa P: Determinants of elevated urinary albumin in the 4,937 type 2 diabetic subjects recruited for the DIABHYCAR study in Western Europe and North Africa. <source>Diabetes Care</source><volume>23</volume> (Suppl. 2):<fpage>B40</fpage>&#x02013;B48, <year>2000</year><pub-id pub-id-type="pmid">10860190</pub-id></citation></ref><ref id="r22"><label>22</label><citation citation-type="journal">Evans AE, Poirier O, Kee F, Lecerf L, McCrum E, Falconer T, Crane J, O'Rourke DF, Cambien F: Polymorphisms of the angiotensin-converting-enzyme gene in subjects who die from coronary heart disease. <source>Q J Med</source><volume>87</volume>:<fpage>211</fpage>&#x02013;214, <year>1994</year><pub-id pub-id-type="pmid">8208911</pub-id></citation></ref><ref id="r23"><label>23</label><citation citation-type="journal">Hadjadj S, Gallois Y, Alhenc-Gelas F, Chatellier G, Marre M, Genes N, Lievre M, Mann J, Menard J, Vasmant D: Angiotensin-I-converting enzyme insertion/deletion polymorphism and high urinary albumin concentration in French Type 2 diabetes patients. <source>Diabet Med</source><volume>20</volume>:<fpage>677</fpage>&#x02013;682, <year>2003</year><pub-id pub-id-type="pmid">12873298</pub-id></citation></ref></ref-list></back><floats-wrap><table-wrap position="float" id="t1"><label>Table 1</label><caption><p>Baseline clinical and biological characteristics according to the <italic>ACE</italic> insertion/deletion polymorphism in the DIABHYCAR trial population</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="center" valign="bottom"/><th colspan="3" rowspan="1" align="center" valign="bottom"><italic>ACE</italic> genotype <hr/></th><th colspan="1" rowspan="2" align="center" valign="bottom"><italic>P</italic> value: II vs. ID vs. DD</th></tr><tr><th colspan="1" rowspan="1" align="center" valign="bottom"/><th colspan="1" rowspan="1" align="center" valign="bottom"><italic>ACE</italic> II</th><th colspan="1" rowspan="1" align="center" valign="bottom"><italic>ACE</italic> ID</th><th colspan="1" rowspan="1" align="center" valign="bottom"><italic>ACE</italic> DD</th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"><italic>n</italic></td><td colspan="1" rowspan="1" align="center" valign="top">549</td><td colspan="1" rowspan="1" align="center" valign="top">1,463</td><td colspan="1" rowspan="1" align="center" valign="top">1,114</td><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Randomization group (placebo/ramipril)</td><td colspan="1" rowspan="1" align="center" valign="top">272 (50)/277 (50)</td><td colspan="1" rowspan="1" align="center" valign="top">723 (49)/740 (51)</td><td colspan="1" rowspan="1" align="center" valign="top">582 (52)/532 (48)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.327</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Age (years)</td><td colspan="1" rowspan="1" align="center" valign="top">65.3 &#x000b1; 8.3</td><td colspan="1" rowspan="1" align="center" valign="top">65.7 &#x000b1; 8.4</td><td colspan="1" rowspan="1" align="center" valign="top">65.7 &#x000b1; 8.2</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.621</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Sex (male/female)</td><td colspan="1" rowspan="1" align="center" valign="top">395 (72)/154 (28)</td><td colspan="1" rowspan="1" align="center" valign="top">1,061 (73)/402 (27)</td><td colspan="1" rowspan="1" align="center" valign="top">828 (74)/286 (26)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.481</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Known diabetes duration (years)</td><td colspan="1" rowspan="1" align="center" valign="top">10.1 &#x000b1; 7.6</td><td colspan="1" rowspan="1" align="center" valign="top">10.3 &#x000b1; 7.7</td><td colspan="1" rowspan="1" align="center" valign="top">10.2 &#x000b1; 7.8</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.802</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Systolic blood pressure (mmHg)</td><td colspan="1" rowspan="1" align="center" valign="top">145 &#x000b1; 15</td><td colspan="1" rowspan="1" align="center" valign="top">145 &#x000b1; 14</td><td colspan="1" rowspan="1" align="center" valign="top">144 &#x000b1; 14</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.331</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Diastolic blood pressure (mmHg)</td><td colspan="1" rowspan="1" align="center" valign="top">82 &#x000b1; 8</td><td colspan="1" rowspan="1" align="center" valign="top">82 &#x000b1; 8</td><td colspan="1" rowspan="1" align="center" valign="top">82 &#x000b1; 9</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.601</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">BMI (kg/m<sup>2</sup>)</td><td colspan="1" rowspan="1" align="center" valign="top">29.6 &#x000b1; 4.6</td><td colspan="1" rowspan="1" align="center" valign="top">29.3 &#x000b1; 4.6</td><td colspan="1" rowspan="1" align="center" valign="top">29.3 &#x000b1; 5.0</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.460</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Baseline urinary albumin (mg/l)</td><td colspan="1" rowspan="1" align="center" valign="top">81 (42&#x02013;227)</td><td colspan="1" rowspan="1" align="center" valign="top">75 (40&#x02013;175)</td><td colspan="1" rowspan="1" align="center" valign="top">75 (39&#x02013;183)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.281</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Smokers (yes/no)<xref ref-type="table-fn" rid="t1fn2">&#x02020;</xref></td><td colspan="1" rowspan="1" align="center" valign="top">80 (17)/401 (83)</td><td colspan="1" rowspan="1" align="center" valign="top">201 (16)/1,054 (84)</td><td colspan="1" rowspan="1" align="center" valign="top">168 (18)/789 (82)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.481</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Serum creatinine (&#x003bc;mol/l)</td><td colspan="1" rowspan="1" align="center" valign="top">88 &#x000b1; 19</td><td colspan="1" rowspan="1" align="center" valign="top">90 &#x000b1; 21</td><td colspan="1" rowspan="1" align="center" valign="top">89 &#x000b1; 20</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.224</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">A1C (&#x00025;)</td><td colspan="1" rowspan="1" align="center" valign="top">8.0 &#x000b1; 1.8</td><td colspan="1" rowspan="1" align="center" valign="top">7.9 &#x000b1; 1.7</td><td colspan="1" rowspan="1" align="center" valign="top">7.8 &#x000b1; 1.8</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.016</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Total cholesterol (mmol/l)</td><td colspan="1" rowspan="1" align="center" valign="top">5.9 &#x000b1; 1.1</td><td colspan="1" rowspan="1" align="center" valign="top">5.8 &#x000b1; 1.1</td><td colspan="1" rowspan="1" align="center" valign="top">5.8 &#x000b1; 1.1</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.239</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">LDL cholesterol (mmol/l)</td><td colspan="1" rowspan="1" align="center" valign="top">3.6 &#x000b1; 0.9</td><td colspan="1" rowspan="1" align="center" valign="top">3.5 &#x000b1; 0.9</td><td colspan="1" rowspan="1" align="center" valign="top">3.5 &#x000b1; 0.9</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.601</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">HDL cholesterol (mmol/l)</td><td colspan="1" rowspan="1" align="center" valign="top">1.3 &#x000b1; 0.3</td><td colspan="1" rowspan="1" align="center" valign="top">1.3 &#x000b1; 0.4</td><td colspan="1" rowspan="1" align="center" valign="top">1.3 &#x000b1; 0.4</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.940</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Total triglycerides (mmol/l)</td><td colspan="1" rowspan="1" align="center" valign="top">1.9 (1.3&#x02013;2.8)</td><td colspan="1" rowspan="1" align="center" valign="top">1.8 (1.3&#x02013;2.7)</td><td colspan="1" rowspan="1" align="center" valign="top">1.8 (1.3&#x02013;2.6)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.564</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">C-reactive protein (mg/l)</td><td colspan="1" rowspan="1" align="center" valign="top">2.9 (1.4&#x02013;6.6)</td><td colspan="1" rowspan="1" align="center" valign="top">3.1 (1.4&#x02013;6.5)</td><td colspan="1" rowspan="1" align="center" valign="top">3.2 (1.5&#x02013;7.0)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.438</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Personal history of myocardial infarction (yes/no)</td><td colspan="1" rowspan="1" align="center" valign="top">39 (7)/510 (93)</td><td colspan="1" rowspan="1" align="center" valign="top">85 (6)/1,378 (94)</td><td colspan="1" rowspan="1" align="center" valign="top">47 (4)/1,067 (96)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.0108</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Personal history of stroke (yes/no)</td><td colspan="1" rowspan="1" align="center" valign="top">17 (3)/532 (97)</td><td colspan="1" rowspan="1" align="center" valign="top">59 (4)/1,404 (96)</td><td colspan="1" rowspan="1" align="center" valign="top">45 (4)/1,069 (96)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.4212</td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as means &#x000b1; SD,</p></fn><fn><p>&#x0002a;medians (25th&#x02013;75th percentile), or <italic>n</italic> (&#x00025;).</p></fn><fn id="t1fn2"><label>&#x02020;</label><p>Missing data for 433 patients.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t2"><label>Table 2</label><caption><p>Incidence of the combined primary end point and of each of its various components, and all-cause death during the DIABHYCAR trial according to the <italic>ACE</italic> insertion/deletion polymorphism</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="2" align="center" valign="bottom">Study end point</th><th colspan="1" rowspan="2" align="center" valign="bottom">All patients</th><th colspan="3" rowspan="1" align="center" valign="bottom"><italic>ACE</italic> genotype <hr/></th><th colspan="1" rowspan="2" align="center" valign="bottom"><italic>P</italic> value (log-rank): II vs. ID vs. DD</th></tr><tr><th colspan="1" rowspan="1" align="center" valign="bottom"><italic>ACE</italic> II</th><th colspan="1" rowspan="1" align="center" valign="bottom"><italic>ACE</italic> ID</th><th colspan="1" rowspan="1" align="center" valign="bottom"><italic>ACE</italic> DD</th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"><italic>n</italic> enrolled</td><td colspan="1" rowspan="1" align="center" valign="top">3,126</td><td colspan="1" rowspan="1" align="center" valign="top">549</td><td colspan="1" rowspan="1" align="center" valign="top">1,463</td><td colspan="1" rowspan="1" align="center" valign="top">1,114</td><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Primary combined end point</td><td colspan="1" rowspan="1" align="center" valign="top">495/3.78 (3.45&#x02013;4.10)</td><td colspan="1" rowspan="1" align="center" valign="top">97/4.20 (3.38&#x02013;5.02)</td><td colspan="1" rowspan="1" align="center" valign="top">230/3.76 (3.28&#x02013;4.23)</td><td colspan="1" rowspan="1" align="center" valign="top">168/3.60 (3.06&#x02013;4.23)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.489</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Cardiovascular death</td><td colspan="1" rowspan="1" align="center" valign="top">208/1.52 (1.31&#x02013;1.72)</td><td colspan="1" rowspan="1" align="center" valign="top">48/1.99 (1.43&#x02013;2.55)</td><td colspan="1" rowspan="1" align="center" valign="top">84/1.30 (1.02&#x02013;1.58)</td><td colspan="1" rowspan="1" align="center" valign="top">76/1.56 (1.22&#x02013;1.91)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.060</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Myocardial infarction (fatal and nonfatal)</td><td colspan="1" rowspan="1" align="center" valign="top">95/0.69 (0.55&#x02013;0.83)</td><td colspan="1" rowspan="1" align="center" valign="top">18/0.74 (0.40&#x02013;1.09)</td><td colspan="1" rowspan="1" align="center" valign="top">49/0.76 (0.55&#x02013;0.97)</td><td colspan="1" rowspan="1" align="center" valign="top">28/0.58 (0.36&#x02013;0.79)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.493</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Stroke (fatal and nonfatal)</td><td colspan="1" rowspan="1" align="center" valign="top">157/1.17 (0.98&#x02013;1.35)</td><td colspan="1" rowspan="1" align="center" valign="top">32/1.36 (0.89&#x02013;1.82)</td><td colspan="1" rowspan="1" align="center" valign="top">73/1.15 (0.89&#x02013;1.42)</td><td colspan="1" rowspan="1" align="center" valign="top">52/1.09 (0.79&#x02013;1.38)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.615</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Heart failure requiring hospitalization</td><td colspan="1" rowspan="1" align="center" valign="top">136/1.00 (0.84&#x02013;1.17)</td><td colspan="1" rowspan="1" align="center" valign="top">21/0.89 (0.51&#x02013;1.27)</td><td colspan="1" rowspan="1" align="center" valign="top">67/1.06 (0.80&#x02013;1.31)</td><td colspan="1" rowspan="1" align="center" valign="top">48/0.99 (0.71&#x02013;1.26)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.769</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">ESRF</td><td colspan="1" rowspan="1" align="center" valign="top">18/0.13 (0.07&#x02013;0.19)</td><td colspan="1" rowspan="1" align="center" valign="top">7/0.29 (0.07&#x02013;0.51)</td><td colspan="1" rowspan="1" align="center" valign="top">8/0.12 (0.04&#x02013;0.21)</td><td colspan="1" rowspan="1" align="center" valign="top">3/0.06 (0.01&#x02013;0.13)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.034</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Death (all-cause)</td><td colspan="1" rowspan="1" align="center" valign="top">455/3.13 (3.01&#x02013;3.61)</td><td colspan="1" rowspan="1" align="center" valign="top">88/3.68 (2.92&#x02013;4.43)</td><td colspan="1" rowspan="1" align="center" valign="top">191/2.95 (2.53&#x02013;3.36)</td><td colspan="1" rowspan="1" align="center" valign="top">176/3.61 (3.09&#x02013;4.14)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.071</td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as <italic>n</italic> or number of events per 100 patient-years (95&#x00025; CI). Primary combined end point: time to cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, nonfatal heart failure requiring hospitalization, or ESRF.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t3"><label>Table 3</label><caption><p>Baseline clinical and biological characteristics according to the ACE insertion/deletion polymorphism in the SURDIAGENE population</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="center" valign="bottom"/><th colspan="3" rowspan="1" align="center" valign="bottom"><italic>ACE</italic> genotype <hr/></th><th colspan="1" rowspan="2" align="center" valign="bottom"><italic>P</italic> value: II vs. ID vs. DD</th></tr><tr><th colspan="1" rowspan="1" align="center" valign="bottom"/><th colspan="1" rowspan="1" align="center" valign="bottom"><italic>ACE</italic> II</th><th colspan="1" rowspan="1" align="center" valign="bottom"><italic>ACE</italic> ID</th><th colspan="1" rowspan="1" align="center" valign="bottom"><italic>ACE</italic> DD</th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"><italic>n</italic></td><td colspan="1" rowspan="1" align="center" valign="top">118</td><td colspan="1" rowspan="1" align="center" valign="top">448</td><td colspan="1" rowspan="1" align="center" valign="top">351</td><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Age (years)</td><td colspan="1" rowspan="1" align="center" valign="top">66.1 &#x000b1; 10.4</td><td colspan="1" rowspan="1" align="center" valign="top">65.2 &#x000b1; 10.6</td><td colspan="1" rowspan="1" align="center" valign="top">64.9 &#x000b1; 10.4</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.604</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Sex (male/female)</td><td colspan="1" rowspan="1" align="center" valign="top">68 (58)/50 (42)</td><td colspan="1" rowspan="1" align="center" valign="top">258 (58)/190 (42)</td><td colspan="1" rowspan="1" align="center" valign="top">184 (52)/167 (48)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.310</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Known diabetes duration (years)</td><td colspan="1" rowspan="1" align="center" valign="top">15.2 &#x000b1; 9.7</td><td colspan="1" rowspan="1" align="center" valign="top">15.1 &#x000b1; 10.1</td><td colspan="1" rowspan="1" align="center" valign="top">15.4 &#x000b1; 10.0</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.909</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Systolic blood pressure (mmHg)</td><td colspan="1" rowspan="1" align="center" valign="top">131 &#x000b1; 16</td><td colspan="1" rowspan="1" align="center" valign="top">135 &#x000b1; 18</td><td colspan="1" rowspan="1" align="center" valign="top">135 &#x000b1; 19</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.103</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Diastolic blood pressure (mmHg)</td><td colspan="1" rowspan="1" align="center" valign="top">72 &#x000b1; 10</td><td colspan="1" rowspan="1" align="center" valign="top">73 &#x000b1; 11</td><td colspan="1" rowspan="1" align="center" valign="top">73 &#x000b1; 11</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.709</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">BMI (kg/m<sup>2</sup>)</td><td colspan="1" rowspan="1" align="center" valign="top">31.0 &#x000b1; 6.8</td><td colspan="1" rowspan="1" align="center" valign="top">31.0 &#x000b1; 5.8</td><td colspan="1" rowspan="1" align="center" valign="top">31.1 &#x000b1; 6.0</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.923</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Baseline urinary albumin (mg/l)</td><td colspan="1" rowspan="1" align="center" valign="top">22 (8&#x02013;95)</td><td colspan="1" rowspan="1" align="center" valign="top">23 (8&#x02013;129)</td><td colspan="1" rowspan="1" align="center" valign="top">25 (8&#x02013;135)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.841</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Smokers (yes/no)<xref ref-type="table-fn" rid="t3fn1">&#x0002a;</xref></td><td colspan="1" rowspan="1" align="center" valign="top">10 (8)/107 (92)</td><td colspan="1" rowspan="1" align="center" valign="top">52 (12)/389 (88)</td><td colspan="1" rowspan="1" align="center" valign="top">30 (8)/317 (92)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.288</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Serum creatinine (&#x003bc;mol/l)</td><td colspan="1" rowspan="1" align="center" valign="top">81.5 (72&#x02013;100)</td><td colspan="1" rowspan="1" align="center" valign="top">84.5 (70&#x02013;104)</td><td colspan="1" rowspan="1" align="center" valign="top">84 (70&#x02013;102)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.488</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">A1C (&#x00025;)</td><td colspan="1" rowspan="1" align="center" valign="top">7.8 &#x000b1; 1.5</td><td colspan="1" rowspan="1" align="center" valign="top">7.9 &#x000b1; 1.5</td><td colspan="1" rowspan="1" align="center" valign="top">7.9 &#x000b1; 1.5</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.673</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Personal history of myocardial infarction (yes/no)</td><td colspan="1" rowspan="1" align="center" valign="top">11 (9)/107 (91)</td><td colspan="1" rowspan="1" align="center" valign="top">62 (14)/386 (86)</td><td colspan="1" rowspan="1" align="center" valign="top">60 (17)/291 (83)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.099</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Personal history of stroke (yes/no)</td><td colspan="1" rowspan="1" align="center" valign="top">4 (3)/114 (97)</td><td colspan="1" rowspan="1" align="center" valign="top">21 (5)/427 (95)</td><td colspan="1" rowspan="1" align="center" valign="top">19 (5)/332 (95)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.665</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">ESRD<xref ref-type="table-fn" rid="t3fn2">&#x02020;</xref></td><td colspan="1" rowspan="1" align="center" valign="top">2 (2)/116 (98)</td><td colspan="1" rowspan="1" align="center" valign="top">6 (1)/442 (99)</td><td colspan="1" rowspan="1" align="center" valign="top">7 (2)/344 (98)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.774</td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as means &#x000b1; SD, medians (25th&#x02013;75th percentile), or <italic>n</italic> (&#x00025;).</p></fn><fn id="t3fn1"><label>&#x0002a;</label><p>Missing data for 12 patients.</p></fn><fn id="t3fn2"><label>&#x02020;</label><p>Percent calculated among nephropathic patients.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t4"><label>Table 4</label><caption><p>Incidence of the combined primary end point and of each of its various components, and all-cause death according to the <italic>ACE</italic> insertion/deletion polymorphism in the SURDIAGENE cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="2" align="center" valign="bottom">Study end point</th><th colspan="1" rowspan="2" align="center" valign="bottom">All patients</th><th colspan="3" rowspan="1" align="center" valign="bottom"><italic>ACE</italic> genotype <hr/></th><th colspan="1" rowspan="2" align="center" valign="bottom"><italic>P</italic> value (log-rank): II vs. ID vs. DD</th></tr><tr><th colspan="1" rowspan="1" align="center" valign="bottom"><italic>ACE</italic> II</th><th colspan="1" rowspan="1" align="center" valign="bottom"><italic>ACE</italic> ID</th><th colspan="1" rowspan="1" align="center" valign="bottom"><italic>ACE</italic> DD</th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"><italic>n</italic> enrolled</td><td colspan="1" rowspan="1" align="center" valign="top">917</td><td colspan="1" rowspan="1" align="center" valign="top">118</td><td colspan="1" rowspan="1" align="center" valign="top">448</td><td colspan="1" rowspan="1" align="center" valign="top">351</td><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Primary combined end point</td><td colspan="1" rowspan="1" align="center" valign="top">187/7.28 (6.28&#x02013;8.29)</td><td colspan="1" rowspan="1" align="center" valign="top">26/8.32 (5.26&#x02013;11.39)</td><td colspan="1" rowspan="1" align="center" valign="top">90/7.11 (5.70&#x02013;8.53)</td><td colspan="1" rowspan="1" align="center" valign="top">71/7.18 (5.57&#x02013;8.78)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.769</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Cardiovascular death</td><td colspan="1" rowspan="1" align="center" valign="top">73/2.68 (2.07&#x02013;3.28)</td><td colspan="1" rowspan="1" align="center" valign="top">15/4.57 (2.31&#x02013;6.83)</td><td colspan="1" rowspan="1" align="center" valign="top">29/2.14 (1.37&#x02013;2.91)</td><td colspan="1" rowspan="1" align="center" valign="top">29/2.77 (1.77&#x02013;3.77)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.057</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Myocardial infarction (fatal and nonfatal)</td><td colspan="1" rowspan="1" align="center" valign="top">31/1.15 (0.75&#x02013;1.55)</td><td colspan="1" rowspan="1" align="center" valign="top">5/1.53 (0.19&#x02013;2.86)</td><td colspan="1" rowspan="1" align="center" valign="top">14/1.04 (0.50&#x02013;1.59)</td><td colspan="1" rowspan="1" align="center" valign="top">12/1.16 (0.50&#x02013;1.81)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.771</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Stroke (fatal and nonfatal)</td><td colspan="1" rowspan="1" align="center" valign="top">25/0.92 (0.56&#x02013;1.28)</td><td colspan="1" rowspan="1" align="center" valign="top">3/0.91 (0.11&#x02013;1.94)</td><td colspan="1" rowspan="1" align="center" valign="top">11/0.81 (0.33&#x02013;1.30)</td><td colspan="1" rowspan="1" align="center" valign="top">11/1.06 (0.43&#x02013;1.68)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.842</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Heart failure requiring hospitalization</td><td colspan="1" rowspan="1" align="center" valign="top">70/2.63 (2.02&#x02013;3.23)</td><td colspan="1" rowspan="1" align="center" valign="top">11/3.45 (1.44&#x02013;5.45)</td><td colspan="1" rowspan="1" align="center" valign="top">29/2.18 (1.40&#x02013;2.97)</td><td colspan="1" rowspan="1" align="center" valign="top">30/2.95 (1.91&#x02013;3.99)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.358</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">ESRF</td><td colspan="1" rowspan="1" align="center" valign="top">26/0.97 (0.60&#x02013;1.34)</td><td colspan="1" rowspan="1" align="center" valign="top">2/0.61 (0.03&#x02013;1.46)</td><td colspan="1" rowspan="1" align="center" valign="top">15/1.13 (0.56&#x02013;1.70)</td><td colspan="1" rowspan="1" align="center" valign="top">9/0.87 (0.30&#x02013;1.43)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.633</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Death (all-cause)</td><td colspan="1" rowspan="1" align="center" valign="top">108/3.93 (3.20&#x02013;4.65)</td><td colspan="1" rowspan="1" align="center" valign="top">20/6.04 (3.47&#x02013;8.61)</td><td colspan="1" rowspan="1" align="center" valign="top">45/3.29 (2.34&#x02013;4.23)</td><td colspan="1" rowspan="1" align="center" valign="top">43/4.08 (2.89&#x02013;5.28)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.125</td></tr></tbody></table><table-wrap-foot><fn><p>Data are <italic>n</italic> and number of events per 100 patient-years (95&#x00025; CI). Primary combined end point: time to cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, nonfatal heart failure requiring hospitalization, or ESRF.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article> 